EXPERIENCE OF RITUXIMAB APPLICATION ON A PATIENT, SUFFERING FROM JUVENILE RHEUMATOID ARTHRITIS
Abstract
Key words: children, treatment, rituximab, juvenile rheumatoid arthritis.
About the Authors
E.I. AlexeevaRussian Federation
T.М. Bzarova
Russian Federation
E.L. Semikina
Russian Federation
S.S. Akulova
Russian Federation
References
1. Johnson P., Glennie M. The mechanism of action of rituximab in the elimination of tumor cells. Semin. Oncol. 2003; 30 (Suppl. 2): 3–8.
2. Насонов Е.Л. Новые направления терапии ревматоидного артрита: перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб). Русский медицинский журнал. 2006; 4 (25): 1–4.
3. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete В lymphocytes. Rheumatology (Oxford). 2001; 40: 205–211.
4. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with В lymphocyte depletion. Ann. Rheum. Dis. 2002; 61: 883–888.
5. De Vita S., Zaja F., Sacco S., De Candia A, Fanin R., Ferraccioli G. Efficacy of selective В cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2029–2033.
6. Kramrn H., Hansen K.E., Gowing E., Bridges A.. Successful therapy of rheumatoid arthritis with rituximab. Renewed interest in the role of В ceils in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 2004; 10: 28–32.
7. Kneitz C, Wilhelm M, Tony HP. improvement of refractory rheumatoid arthritis after depletion of B cells. Scan. J. Rheumatol. 2004; 33: 82–86.
8. Cambridge G., Leandro M.J., Edwards J.C., et al. Serologic changes following В lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003; 48: 2146–2154.
9. Насонов Е.Л. Перспективы применения монокпональных антител в В–лимфоцитам (ритуксимаб) при ревматоидном артрите. Клиническая фармакология терапия. 2006; 1 (5): 55-58.
10. Edwards C.W., Szczepanski L., Szechinski J. et al. Efficacy of B–cell Targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl. J. Med. 2005; 350: 2572–2581.
11. Emery P., Fleishmann R., Filipowicz-Sospowska A., et al. for the DANCER Study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase lib randomized, double blind, placebo controlled dose-range trial. Arthritis Rheum. 2006; 54: 1390–1400.
12. Алексеева Е.И., Алексеева А.М., Бзарова Т.М. и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 2 (2): 20–30.
13. Martini G., Zulian F. Juvenile idiopathic arthritis: current and future treatment option. Expert Opion. Pharmacother. 2006; 7 (4): 387–399.
Review
For citations:
Alexeeva E., Bzarova T., Semikina E., Akulova S. EXPERIENCE OF RITUXIMAB APPLICATION ON A PATIENT, SUFFERING FROM JUVENILE RHEUMATOID ARTHRITIS. Current Pediatrics. 2006;5(6):96-100.
Email this article 
